PresentationGlobal Industrial Tech and Mobility Conference. We're very excited to have Chris Calio, RTX's Chairman and CEO, for a chat with us about a lot of different themes in aerospace and defense. Chris, if you have any initial comments, I want to pass it off to you, and then we'll hit it.Christopher CalioChairman & CEO Well, thanks, John, and great to be here this morning with everybody. Maybe just one housekeeping item, of course, may be making some forward-looking statements today, subject to all tho ...

Press release – Neuilly-sur-Seine, Wednesday, February 18, 2026 – 5.45 pm ARGAN signed a new 10,000 sq.m lease for its AutOnom® warehouse in Augny (57) ARGAN announced the re-letting of its AutOnom® logistics site located in Augny (57), in the Metz area, to MPM Group, a leading company in professional sound, lighting, video, and stage structure solutions. Located on the Frescaty plateau in Augny (57), opposite the 185,000 sq.m ARGAN warehouse leased to AMAZON, this latest-generation logistics platform offer ...

Summary of CRISPR Therapeutics Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: Virtual Oncology Leadership Summit - **Date**: February 18, 2026 Key Points Industry Focus - CRISPR Therapeutics is engaged in multiple disease areas, with a strong focus on oncology, cardiovascular diseases, autoimmune diseases, and Type 1 diabetes [3][4] Oncology Programs - **ZugoCell (formerly CTX112)**: A next-generation allogeneic CAR-T therapy targeting CD19, designed to improve potency and safety compared to earlier generations [4][5] - **Allogeneic CAR-T**: Made from healthy donor-derived cells, with advanced edits to enhance efficacy and safety, aiming for autologous-like performance [5][6] Key Edits in ZugoCell - **Beta-2M Knockout**: Prevents immune system from recognizing allogeneic cells as foreign, enhancing persistence [8][9] - **RGNASE1 Knockout**: Retains a naive T cell phenotype, allowing for better expansion and reduced exhaustion [10][11] - **TGF-beta Receptor 2 Knockout**: Prevents exhaustion of CAR-T cells, enhancing potency [10][11] Clinical Strategy - **Autoimmune Diseases**: Rapidly enrolling patients for indications like lupus, myositis, and scleroderma, with plans to expand further [17][18] - **Oncology**: Aiming for high complete response (CR) rates and durability, with initial CR rates for ZugoCell reaching nearly 70% [20][21] Regulatory Pathway - Parallel development in oncology and autoimmune indications, with discussions with regulators expected to guide future trials [27][28] Pricing Strategy - Targeting a price point of around $200K for allogeneic CAR-T therapies, significantly lower than current autologous therapies priced at $350K-$400K [52][53] In Vivo CAR-T Development - Developing both transient and permanent CAR-T therapies using LNP-mediated delivery, with a focus on safety and efficacy [54][55] - Permanent CARs could potentially eliminate tumors with a single injection, offering a significant advancement in oncology [56][57] Market Opportunities - Significant potential in both U.S. and international markets, particularly in regions where autologous therapies are not feasible due to cost and availability [48][49] Future Directions - Continued focus on data collection and analysis in both oncology and autoimmune spaces, with a strong emphasis on achieving long-term remissions and safety [31][32][39] Conclusion - CRISPR Therapeutics is positioned to make significant advancements in both oncology and autoimmune therapies through innovative CAR-T technologies, with a clear strategy for regulatory approval and market entry.

PresentationAdam SeidenBarclays Bank PLC, Research Division All right. Hate to interrupt the smooth jazz, but we'll get going here. So my name is Adam Seiden. I lead the U.S. machinery and construction effort here at Barclays. Thanks for joining us again for the Industrials Conference. So for this session here, we have the folks from Jacobs. So we have both Bob and Venk, CEO and CFO. So really excited for these guys to be joining us. From the -- for the format of this session, like a lot of the others here ...

Euronext publishes Q4 and full year 2025 results In 2025, Euronext delivered another year of double-digit growth, driven by the expansion of non-volume-related businesses, resilient trading, clearing revenues and cost discipline. Euronext will accelerate the execution of its strategic plan in 2026. Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 18 February 2026 – Euronext, the leading European capital market infrastructure, today publishes its results for the fourth quarter and full ye ...

Question-and-Answer SessionSo very excited to talk about a lot of developments here on the M&A front and on your business. But for those that have done this already, let's just queue up question number one for the audience real quick. Do you currently own UNP? Yes, overweight, market weight, 3 underweight or 4, no.Brandon OglenskiBarclays Bank PLC, Research Division Okay. That's [indiscernible] favorably. Question number two, please. And your -- what's your general bias towards Union Pacific right now, posi ...

Marimekko Corporation, Stock Exchange Release, 18 February 2026 at 18.45 p.m. EET Marimekko Corporation: Repurchase of own shares on 18 February 2026 Marimekko Corporation (LEI: 74370053IOY42B9YJ350) has acquired its own shares (ISIN FI0009007660) as follows: Trade date18 February 2026Bourse tradeBuyShareMEKKOVolume5,955Average price/share, EUR11.3356Total price, EUR67,503.50 On 12 February 2026, Marimekko announced that it will start acquiring the company’s own shares based on the authorization granted by ...

PRESS RELEASE February 18, 2026 Evolution in the composition of the Board of Directors Boulogne-Billancourt, February 18, 2026 – The Board of Directors of Renault, during its meeting held today, decided, upon recommendation of the Governance and Compensation Committee, to propose to the Shareholders’ General Meeting of April 30, 2026, the appointment of Marie-José Donsion as an independent director for a four-year period. She will succeed Pierre Fleuriot, whose term of office expires at the end of the Share ...

If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.Amazon.com, Inc. ( AMZN ) stock has lost 17% since my last report . The stock price decline was driven by tech sector weakness as investors process growing capital expenditures with an apparent lack ofDhierin-Perkash Bechai is an aerospace, defense ...

LO Centered Marketing, Credit Score Products; Company-Sponsored Events; Faith Schwartz Interview On today’s Mortgage Matters live interview (at 1PM ET; feel free to ask questions) Faith Schwartz, who has an incredible pedigree, draws upon her decades of housing finance and policy experience to discuss crisis leadership lessons, regulatory evolution, and what today’s lenders should be watching as the market recalibrates. One topic could very well be the FHFA rolling back Fair Housing Rules: The Federal agen ...